Related Experiment Video
Updated: Dec 26, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Polatuzumab Vedotin: a New Target for B Cell Malignancies
Yun Choi1, Catherine S Diefenbach2
1Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York University School of Medicine & Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA.
Polatuzumab vedotin shows promise for treating B cell malignancies like diffuse large B cell lymphoma (DLBCL). Ongoing research explores combinations to optimize therapy for relapsed or refractory non-Hodgkin lymphoma (NHL).
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Antibody-drug conjugates represent a novel therapeutic class for B cell malignancies.
- Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) are significant B cell malignancies.
Purpose of the Study:
- To review recent advancements in polatuzumab vedotin therapy.
- Focus on its application in relapsed or refractory DLBCL and FL.
Main Methods:
- Review of clinical trial data and published literature.
- Analysis of polatuzumab vedotin in combination regimens.
Main Results:
- Polatuzumab vedotin gained FDA approval for relapsed/refractory DLBCL in combination with bendamustine and rituximab.
- Early trials indicate promising results with various combination partners including chemoimmunotherapy, immunomodulators, bispecific antibodies, and venetoclax.
Conclusions:
- Polatuzumab vedotin offers a new therapeutic avenue for relapsed/refractory NHL.
- Further research is required to establish optimal combination strategies for both relapsed/refractory and newly diagnosed NHL.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers